Intendis, Inc. Changes Name to Bayer HealthCare

MORRISTOWN, N.J., Jan. 4, 2012 /PRNewswire/ -- Five years after being acquired by Bayer, Intendis, Inc., makers of dermatology brands Finacea® (azelaic acid) Gel, 15% and Desonate® (desonide) Gel 0.05%, will change its name to Bayer HealthCare.  Under this new name, the unit will continue to build on Intendis' long-standing dedication to dermatologists, patients and passion for skin health.

"Although Intendis, Inc. will have a new name and a new look, the company's pioneering tradition in dermatology remains at the heart of everything we do," said Bill Griffing, U.S. President and General Manager for Bayer HealthCare's Dermatology Unit. "During the past five years, we have focused on bringing together the best of both Intendis, Inc. and Bayer HealthCare to better serve our customers. Clarifying our place in the Bayer family with this name change increases our access to talented experts and resources that will allow us to continue to develop new therapies to improve skin health and the lives of patients with skin conditions."

While all Intendis, Inc. branding will be changed to reflect the Bayer brand, there will be no changes in the well-established organization, structure, or product quality of the company. The points of contact assisting physicians, pharmacists and partner companies remain the same. Intendis, Inc. has been an integrated part of the Bayer organization's Consumer Care division since 2006, when Bayer acquired Schering AG. 

"The name change from Intendis, Inc. to Bayer HealthCare represents a larger shift in our company's model - from a focus on products, to a broader, more value-based approach in healthcare," said Griffing. "We remain committed to both of our products Finacea® (azelaic acid) Gel, 15% and Desonate® (desonide) Gel 0.05% - and to finding ways to bring new advancements to market using Bayer's extensive R&D capabilities."

About Bayer HealthCare's Dermatology Unit
Bayer HealthCare's Dermatology Unit is a specialized global pharmaceutical company focused solely in dermatology. It is headquartered in Berlin, and was founded in 2005 as a subsidiary of Schering AG, Germany. Today, Dermatology is part of the Bayer Group with commercial operations around the globe. The affiliate in the United States is headquartered in Morristown, NJ, and currently offers the following products:  Finacea® (azelaic acid) Gel, 15% and Desonate® (desonide) Gel 0.05%.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 16.9 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Contact:
Kate Fisher, 212 880 5204
E-Mail: [email protected]

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no obligation whatsoever to update these forward-looking statements or to adjust them to include future events or developments.

SOURCE Bayer HealthCare